Genetic Testing Market Trends 2032: Rise in Direct-to-Consumer (DTC) Tests
Genetic Testing Market Trends 2032: Rise in Direct-to-Consumer (DTC) Tests
The genetic testing services market is growing rapidly as healthcare embraces precision medicine and preventive care. These services include predictive risk assessments, carrier screening, pharmacogenomic profiling, oncology panels, and ancestry testing. Fueling this growth are technological breakthroughs like next-generation sequencing (NGS) and whole-exome sequencing, reduced testing costs, rising genetic disorder prevalence, and expanding direct-to-consumer (DTC) access. North America leads the market, while Asia-Pacific shows the quickest expansion. With continued innovation, increased patient awareness, and supportive genomic initiatives, genetic testing is becoming a cornerstone of modern diagnostics and personalized healthcare.
According to Fortune Business Insights, the global genetic testing market was valued at USD 33.82 billion in 2024. The market is projected to grow from USD 37.32 billion in 2025 to USD 76.09 billion by 2032, exhibiting a CAGR of 10.7% during the forecast period. In 2024, North America dominated the genetic testing market with a market share of 41.72%.
Hoffmann‑La Roche Ltd. (Switzerland)
Illumina, Inc. (U.S.)
Thermo Fisher Scientific Inc. (U.S.)
Bio‑Rad Laboratories, Inc. (U.S.)
Oxford Nanopore Technologies plc. (U.K.)
Laboratory Corporation of America Holdings (U.S.)
Agilent Technologies, Inc. (U.S.)
Myriad Genetics, Inc. (U.S.)
QIAGEN (Germany)
Quest Diagnostics Incorporated (U.S.)
Danaher Corporation (U.S.)
In May 2023, Laboratory Corporation of America (Labcorp) entered into a strategic agreement with Jefferson Health. The partnership is expected to enhance the capacity and scope of specialty genetic testing services—and aligns with the market's growing demand.
Rising Chronic Illness Prevalence: Increasing rates of diabetes, cancer, cystic fibrosis, sickle cell disease, Down syndrome, and autoimmune disorders are driving demand. Sickle cell disease cases rose by 41% from 2000 to 2021.
Technological Advancements: Next‑Generation Sequencing (NGS), high-throughput screening, microarrays, and PCR have enhanced test accuracy and scalability.
Shift to Personalized Medicine: Pharmacogenomics enables tailored drug therapies—boosting both adoption and test volume.
Direct‑to‑Consumer (DTC) Trends: Growth in consumer genetic testing services—often ordered without clinical oversight—is expanding market reach.
High Costs: The cost of advanced testing tools and clinical laboratory infrastructure presents a significant entry barrier.
Regulation & Ethics: Evolving data privacy rules and ethical concerns over genetic information may hinder growth.
The market encompasses both test products and services. In 2024, the services segment led the market, reflecting trends toward outsourced lab testing and integrated reporting.
The key technologies driving market growth include:
NGS: Enables entire genome or exome sequencing at scale.
PCR: Gold-standard for targeted mutation detection.
Microarrays & In-Situ Hybridization: Useful for SNP genotyping and chromosomal microdeletions.
The primary medical applications include oncology, rare and inherited diseases, pharmacogenomics, reproductive disorders, and prenatal screening. Oncology continues to hold the largest market share, supported by its high disease burden.
Dominating the global market with 41.72% share in 2024, North America reached USD 14.11 billion. Key drivers include widespread genetic disorder awareness, advanced diagnostic infrastructure, and strong personalized medicine push. The rise of DTC testing further fuels regional growth.
Europe shows moderate yet consistent growth. Robust healthcare systems, national screening programs, and widespread R&D investment—especially in Germany, UK, and France—support adoption of advanced testing platforms.
This region is expected to exhibit the highest CAGR through 2032. Factors include rising healthcare spending, expanded genetic disorder prevalence (thalassemia, sickle cell anemia), improved testing infrastructure, and government-led genetic screening initiatives.
Though currently smaller, markets in Latin America and the Middle East & Africa are gaining traction—driven by enhanced screening programs and private-sector healthcare investment.
📦 High-throughput workflows: Integration of NGS panels supporting oncology and rare disease diagnostics.
🧬 Pharmacogenomics expansion: Tailored therapy testing is becoming standard in cancer, cardiovascular, and psychiatric care.
🏙 DTC commercialization: Services now reach attendees through online portals and genomic wellness platforms.
📊 Health informatics integration: Combining EHR systems and genotypic results into clinical workflows is increasing adoption rates.
Market competition is intense and innovation-driven. Leading players—Hoffmann‑La Roche, Illumina, Thermo Fisher, QIAGEN, and Quest Diagnostics—are expanding their portfolios via NGS assays, microarray kits, and pharmacogenomic platforms. Labcorp’s May 2023 partnership underscores strategic alliances as a key market strategy.
Explore the full research report with detailed insights and TOC:https://www.fortunebusinessinsights.com/genetic-testing-service-market-105590
The genetic testing market is projected to witness robust expansion through 2032, driven by several catalysts:
Scaling of population-wide genomic screening under national health programs.
Next-gen sequencing and CRISPR‑based diagnostics enhancing accuracy and adaptability.
Genetic counseling via telehealth to facilitate test interpretation and ethical usage.
Regulatory reforms aimed at balancing patient privacy with innovation.
These factors, combined with consumer interest and clinical adoption, position the genetic testing sector for sustained double-digit growth.
The global genetic testing market is entering a new era driven by healthcare digitization, genetic medicine, and consumer-centered strategies. Forecasts suggest growth from USD 33.82 billion in 2024 to USD 76.09 billion by 2032, with sustained double-digit CAGR and North America firmly in the lead. As technologies become more affordable and integrated, this market represents a transformative frontier for patient care and personalized medicine.
About Us:
Fortune Business Insights provides expert corporate analysis and accurate data, enabling businesses of all sizes to make timely decisions. We offer customized solutions tailored to each client’s needs, helping them address unique challenges. Our goal is to empower clients with holistic market intelligence and offer granular insights into the market they operate in.
Our reports are a blend of quantitative and qualitative analysis, aimed at helping businesses achieve sustainable growth. Our experienced analysts and consultants use leading research methodologies to provide comprehensive market assessments enriched with relevant data.
Contact us:
Fortune Business Insights™ Pvt.
Phone: USA: +1 833 909 2966 (Toll-Free),
United Kingdom: +44 808 502 0280 (Toll-Free),
APAC: +91 744 740 1245
Email: sales@fortunebusinessinsights.com